natgillin/translations-raw huggingface dataset:
Samtidig indtagelse af rasagilin og pethidin er kontraindiceret (se pkt.
The concomitant administration of rasagiline and pethidine is contraindicated (see section 4.3).
• Allergisk reaktion
• allergy
I parentes er incidensen af bivirkninger (i procent af patienterne) angivet for henholdsvis rasagilin og placebo.
In parentheses is the adverse reaction incidence (% of patients) in rasagiline vs. placebo, respectively.
In vitro forsøg viser, at begge metaboliseringsveje for rasagilin er afhængig af cytokrom P450 systemet med CYP1A2 som det vigtigste isoenzym i metaboliseringen af rasagilin.
In vitro experiments indicate that both routes of rasagiline metabolism are dependent on cytochrome P450 system, with CYP1A2 being the major iso-enzyme involved in rasagiline metabolism.
Nedsat leverfunktion: Hos forsøgspersoner med let nedsat leverfunktion blev AUC og Cmax øget med hhv. 80% og 38%.
Hepatic impairment: In subjects with mild hepatic impairment, AUC and Cmax were increased by 80% and 38%, respectively.
Der kan forekomme tilfælde af ludomani, øget libido, hyperseksualitet, overdrevent indkøbsmønster, uhæmmet madindtagelse og tvangsspisning hos patienter i behandling med dopaminagonister og/eller anden behandling med dopaminerg virkning.
Pathological gambling, increased libido, hypersexuality, compulsive spending or buying, binge eating and compulsive eating can occur in patients treated with dopamine agonists and/or other dopaminergic treatments.
Hos forsøgspersoner med moderat nedsat leverfunktion blev AUC og Cmax øget med hhv. 568% og 83% (se pkt.
In subjects with moderate hepatic impairment, AUC and Cmax were increased by 568% and 83%, respectively (see section 4.4).
Tag ikke Rasagilin Mylan hvis De er allergisk over for rasagilin eller et af de øvrige indholdsstoffer i Rasagilin Mylan (anført i punkt 6) hvis De lider af alvorlige leverlidelser
Do not take Rasagiline Mylan: - if you are allergic to rasagiline or any of the other ingredients of this medicine (listed in section 6).
For MAO-hæmmere foreligger der rapporter om lægemiddelinteraktion ved samtidig indtagelse af sympatomimetika.
With MAO inhibitors there have been reports of medicinal product interactions with the concomitant use of sympathomimetic medicinal products.
Hvis De mener, at De har taget for mange Rasagilin Mylan tabletter, skal De straks kontakte Deres læge eller apotek.
If you take more Rasagiline Mylan than you should If you think that you may have taken too many Rasagiline Mylan tablets, contact your doctor or pharmacist immediately.
• Slagtilfælde (cerebrovaskulært tilfælde)
• stroke (cerebrovascular accident)
Hver tablet indeholder rasagilintartrat svarende til 1 mg rasagilin.
Each tablet contains rasagiline tartrate corresponding to 1 mg rasagiline.
Den gennemsnitlige totale reduktion i ”off” timer pr. dag var omtrent det samme i entakapongruppen (0,80 timer, 95% CI [1,20; 0,41], p<0,0001) som i rasagilin 1 mg gruppen.
The mean total daily decrease in the OFF time was similar in the entacapone group (-0.80h, 95% CI [-1.20, -0.41], p<0.0001) to that observed in the rasagiline 1 mg group.
• Unormale blodprøveresultater (leukopeni (nedsat antal hvide blodlegemer))
• abnormal results of blood tests (leucopenia)
I undersøgelse III var den gennemsnitlige forskel sammenlignet med placebo 0,94 timer, 95% CI [1,36; 0,51], p<0,0001.
In study III, the mean difference compared to placebo was -0.94h, 95% CI [-1.36, -0.51], p<0.0001.
Effekten var tydelig, om end beskeden, i patientgruppen med Parkinsons sygdom i tidligt stadie.
The effect was evident, although its magnitude was modest in this patient population with mild disease.
Der bør udvises forsigtighed ved iværksættelse af behandling med rasagilin hos patienter med let nedsat leverfunktion.
Caution should be used when initiating treatment with rasagiline in patients with mild hepatic impairment.
Almindelig: Hallucinationer (2,9% vs. 2,1%), abnorme drømme (2,1% vs. 0,8%) Ikke almindelig: Forvirring (0,8% vs. 0,5%) Nervesystemet
Common: hallucinations (2.9% vs. 2.1%), abnormal dreams (2.1% vs. 0.8%) Uncommon: confusion (0.8% vs. 0.5%)
• Kvalme og opkastning
• nausea and vomiting
Nedenstående bivirkninger blev observeret med en højere incidens i placebokontrollerede undersøgelser hos patienter i behandling med 1 mg rasagilin dagligt (rasagilingruppen n=380, placebogruppen n=388).
The list below includes adverse reactions which were reported with a higher incidence in placebo controlled studies in patients receiving 1 mg/day rasagiline (rasagiline group n=380, placebo group n=388).
Overdosering kan forbindes med signifikant hæmning af både MAO-A og MAO-B. I en enkeltdosisundersøgelse fik raske frivillige 20 mg dagligt, og i en 10 dages undersøgelse fik raske frivillige 10 mg dagligt.
In a single-dose study healthy volunteers received 20 mg/day and in a ten-day study healthy volunteers received 10 mg/day.
Brug af rasagilin til patienter med alvorligt nedsat leverfunktion er kontraindiceret (se pkt.
Rasagiline use in patients with severe hepatic impairment is contraindicated (see section 4.3).
Ikke almindelig: Nedsat appetit (0,7% vs. 0%) Psykiske forstyrrelser
Uncommon: decreased appetite (0.7% vs. 0%) Psychiatric disorders
Almindelig: Influenza (4,7% vs. 0,7%)
Common: influenza (4.7% vs. 0.7%)
I undersøgelse II var den gennemsnitlige forskel i antallet af timer tilbragt i ”off” tilstand sammenlignet med placebo 0.78 timer, 95% CI [1,18; 0,39], p=0,0001.
In study II, the mean difference in the number of hours spent in the “OFF” state compared to placebo was -0.78h, 95% CI [-1.18, -0.39], p=0.0001.
Samtidig indtagelse af rasagilin og dextromethorfan eller sympatomimetika, såsom de der findes i nasale og orale ekspektorantia, eller lægemidler mod forkølelser, der indeholder ephedrin eller pseudoephedrin, anbefales ikke (se pkt.
The concomitant use of rasagiline and dextromethorphan or sympathomimetics such as those present in nasal and oral decongestants or cold medicinal product containing ephedrine or pseudoephedrine is not recommended (see section 4.5).
Hos patienter i behandling med Rasagilin Mylan og/eller andre lægemidler til behandling af Parkinsons sygdom er der set tvangshandlinger, tvangstanker, afhængighedspræget spillelyst, overdrevent pengeforbrug, impulshandling og en unormalt stor sexlyst eller en stigning i seksuelle tanker og følelser.
In patients taking Rasagiline Mylan and/or other medications used to treat Parkinson's disease, behaviours such as compulsions, obsessive thoughts, addictive gambling, excessive spending, impulsive behaviour and an abnormally high sex drive or an increase in sexual thoughts or feelings have been observed.
Enhver mistænkelig hudforandring bør diskuteres med Deres læge.
You should speak with your doctor about any suspicious skin changes.
Tabletterne findes i blisterpakninger med 7, 10, 28, 30, 100 og 112 tabletter og i perforerede blisterpakninger med 7 x 1, 10 x 1, 28 x 1, 30 x 1, 100 x 1 og 112 x 1 tabletter.
The tablets are available in blister packs of 7, 10, 28, 30, 100 and 112 tablets and in perforated blister packs containing 7 x 1, 10 x 1, 28 x 1, 30 x 1, 100 x 1 and 112 x 1 tablets.
Det skal De vide, før De begynder at tage Rasagilin Mylan 3.
What you need to know before you take Rasagiline Mylan 3.
Almindelig: Conjunctivitis (2,7% vs. 0,7%)
Common: conjunctivitis (2.7% vs. 0.7%)
Mylan bvba/sprl Tel: + 32 (0)2 658 61 00 (Belgique/Belgien)
Luxembourg/Luxemburg Mylan bvba/sprl Tel: +32 (0)2 658 61 00 (Belgique/Belgien)
Hvis patientens leverfunktion udvikler sig fra at være let nedsat til moderat nedsat, bør behandlingen med rasagilin seponeres (se pkt.
In case patients progress from mild to moderate hepatic impairment, rasagiline should be stopped (see section
Rasagilin Mylan tabletter fås som hvide til grålighvide, aflange (cirka 11,5 mm x 6 mm store), bikonvekse tabletter, præget på den ene side med ”R9SE” og ”1” på den anden side.
What Rasagiline Mylan looks like and contents of the pack Rasagiline tablets are presented as white to off-white, oblong (approximately 11.5 mm x 6 mm) biconvex tablets, debossed with ‘R9SE' on one side and ‘1' on the other side.
sjældne tilfælde af hypertensiv krise, som forbindes med indtagelse af en ukendt mængde føde med et højt tyraminindhold, hos patienter i behandling med rasagilin.
In the post-marketing period, cases of elevated blood pressure, including rare cases of hypertensive crisis associated with ingestion of unknown amounts of tyramine-rich foods, have been reported in patients taking rasagiline.
Hvad angår samtidig indtagelse af rasagilin og selektive serotoningenoptagelseshæmmere (SSRI'ere)/ selektive serotonin-/noradrenalingenoptagelseshæmmere (SNRI'ere) i kliniske undersøgelser henvises der til pkt.
For concomitant use of rasagiline with selective serotonin reuptake inhibitors (SSRIs)/selective serotonin-norepinephrine reuptake inhibitors (SNRIs) in clinical trials, see section 4.8.
Set i lyset af rasagilins MAO-hæmmende virkning anbefales samtidig indgivelse af rasagilin og dextromethorfan derfor ikke (se pkt.
Therefore, in view of the MAO inhibitory activity of rasagiline, the concomitant administration of rasagiline and dextromethorphan is not recommended (see section 4.4).
Rasagilin Mylan 1 mg tabletter rasagilin
Rasagiline Mylan 1 mg tablets rasagiline
Det sekundære effektmål var en global vurdering af forbedringen, foretaget af den undersøgende læge, ved brug af Activities of Daily Living (ADL) subskala til måling i ”off-periode” og UPDRS til måling af motorisk funktionsevne i ”on-periode”.
The secondary measures of efficacy included global assessments of improvement by the examiner, Activities of Daily Living (ADL) subscale scores when OFF and UPDRS motor while ON. Rasagiline produced statistically significant benefit compared to placebo.
Nedenstående bivirkninger blev indberettet med en højere incidens i placebokontrollerede undersøgelser hos patienter i behandling med 1 mg rasagilin dagligt (rasagilingruppen n=149, placebogruppen n=151).
The list below includes adverse reactions which were reported with a higher incidence in placebo controlled studies, in patients receiving 1 mg/day rasagiline (rasagiline group n=149, placebo group n=151).
perforeret enkeltdosisblisterpakning med 7 x 1, 10 x 1, 28 x 1, 30 x 1, 100 x 1 eller 112 x 1 tabletter
Perforated unit dose blister packs of 7 x 1, 10 x 1, 28 x 1, 30 x 1, 100 x 1 or 112 x 1.
Der bør gå mindst fem uger fra seponering af fluoxetin til iværksættelse af behandling med rasagilin.
At least five weeks should elapse between discontinuation of fluoxetine and initiation of treatment with rasagiline.
Efter markedsføring er disse symptomer også set hos patienter i behandling med rasagilin for Parkinsons syge.
In post-marketing experience these symptoms have also been observed in Parkinson's disease patients treated with rasagiline.
Spørg Deres læge til råds, inden De tager et af følgende lægemidler sammen med Rasagilin Mylan: Visse former for lægemidler til behandling af depression (selektive serotoningenoptagelseshæmmere, selektive serotonin-/noradrenalingenoptagelseshæmmere, tricykliske eller tetracykliske antidepressive lægemidler) antibiotikummet ciprofloxacin til behandling af infektioner det hostestillende middel dextromethorphan øjendråber, næsedråber/-spray og slimløsende lægemidler til næse og svælg, der indeholder sympatomimetika, samt forkølelsesmedicin, der indeholder ephedrin eller pseudoephedrin
Certain antidepressants (selective serotonin reuptake inhibitors, selective serotonin-norepinephrine reuptake inhibitors, tricyclic or tetracyclic antidepressants) the antibiotic ciprofloxacin used against infections the cough suppressant dextromethorphan sympathomimetics such as those present in eye drops, nasal and oral decongestants and cold medicine containing ephedrine or pseudoephedrine
I undersøgelse I blev 404 patienter randomiseret til behandling med enten placebo (138 patienter), rasagilin 1 mg dagligt (134 patienter) eller rasagilin 2 mg dagligt (132 patienter) i 26 uger; man sammenlignede ikke med et andet aktivt stof.
In study I, 404 patients were randomly assigned to receive placebo (138 patients), rasagiline 1 mg/day (134 patients) or rasagiline 2 mg/day (132 patients) and were treated for 26 weeks, there was no active comparator.
lægemidler og naturlægemidler i håndkøb, f.eks. perikon), da der er risiko for non-selektiv MAO hæmning, som kan medføre hypertensive kriser (se pkt.
Rasagiline must not be administered along with other MAO inhibitors (including medicinal and natural products without prescription e.g. St. John's Wort) as there may be a risk of non-selective MAO inhibition that may lead to hypertensive crises (see section 4.3).
Almindelig: Dystoni (2,4% vs. 0,8%), karpaltunnelsyndrom (1,3% vs. 0%), balanceforstyrrelser (1,6% vs. 0,3%)
Common: dystonia (2.4% vs. 0.8%), carpal tunnel syndrome (1.3% vs. 0%), balance disorder (1.6% vs. 0.3%)
Sådan skal De tage Rasagilin Mylan 4.
How to take Rasagiline Mylan 4.
Hvis De har glemt at tage Rasagilin Mylan
If you forget to take Rasagiline Mylan
Farmakoterapeutisk klassifikation: Antiparkinsonmiddel, monoaminooxidase-B-hæmmer.
Pharmacotherapeutic group: Anti-Parkinson drugs, Monoamine oxidase-B inhibitors, ATC code: N04BD02
Rasagilin Mylan kan tages i forbindelse med et måltid eller uden for måltiderne.
Rasagiline Mylan may be taken with or without food.
• Fald
• fall
Efter markedsføringen har patienter i samtidig behandling med antidepressiva/SNRI og rasagilin indberettet tilfælde af serotoninsyndrom, som forbindes med agitation, forvirring, rigiditet, pyreksi og myoklonus.
In the post-marketing period, cases of serotonin syndrome associated with agitation, confusion, rigidity, pyrexia and myoclonus have been reported by patients treated with antidepressants/SNRI concomitantly with rasagiline.
I undersøgelse II blev patienterne randomiseret til behandling i 18 uger med enten placebo (229 patienter) eller rasagilin 1 mg dagligt (231 patienter) eller til behandling med 200 mg entakapon, en katekol-O-metyltransferase (COMT) hæmmer (227 patienter), i kombination med levodopa (LD)/decarboxylasehæmmer.
In study II, patients were randomly assigned to receive placebo (229 patients), or rasagiline 1 mg/day (231 patients) or the catechol-O-methyl transferase (COMT) inhibitor, entacapone, 200 mg taken along with scheduled doses of levodopa (LD)/decarboxylase inhibitor (227 patients), and were treated for 18 weeks.
Mylan Pharmaceuticals.s.r.o.
Česká republika Mylan Pharmaceuticals s.r.o.
Dosisjustering er ikke nødvendig ved nedsat nyrefunktion.
Renal impairment No change in dose is required for renal impairment.
Advarsler og forsigtighedsregler Kontakt lægen, før De tager Rasagilin Mylan hvis De lider af let til moderat leverlidelse hvis De oplever mistænkelige hudforandringer.
Warnings and precautions Talk to your doctor before taking Rasagiline Mylan.
I undersøgelse III blev patienterne randomiseret til behandling i 26 uger med enten placebo (159 patienter), rasagilin 0,5 mg dagligt (164 patienter) eller rasagilin 1 mg dagligt (149 patienter).
In study III, patients were randomly assigned to receive placebo (159 patients), rasagiline 0.5 mg/day (164 patients), or rasagiline 1 mg/day (149 patients), and were treated for 26 weeks.
Efter produktet er kommet på markedet, er disse symptomer også set hos patienter i behandling med rasagilin for Parkinsons syge.
In post-marketing experience, these symptoms have also been observed in Parkinson's disease patients treated with rasagiline.
• Øjenbetændelse med røde øjne (conjunctivitis)
• bloodshot eyes (conjunctivitis)
Samtidig indtagelse af rasagilin og fluoxetin eller fluvoxamin bør undgås (se pkt.
The concomitant use of rasagiline and fluoxetine or fluvoxamine should be avoided (see section 4.5).
• Ufrivillige bevægelser af kroppen (dystoni)
• prolonged muscle contractions (dystonia)
Ikke almindelig: Angina pectoris (0,5% vs. 0%) Vaskulære sygdomme
Uncommon: angina pectoris (0.5% vs. 0%)
• Influenza
• flu (influenza)
Almindelig: Vertigo (2,7% vs. 1,3%) Hjerte
Common: vertigo (2.7% vs. 1.3%)
Gennemsnitlig distributionsvolumen efter en enkelt intravenøs dosis rasagilin er 243 l. Plasmaproteinbindingen efter en enkelt peroral 14C-mærket dosis rasagilin er ca. 60-70%.
The mean volume of distribution following a single intravenous dose of rasagiline is 243 l.
• Meget almindelig (kan forekomme hos flere end 1 ud af 10 personer)
• Very common (may affect more than 1 in 10 people)
Der er observeret alvorlige bivirkninger ved samtidig indtagelse af SSRI'ere, SNRI'ere, tricykliske og tetracykliske antidepressiva samt MAO-hæmmere.
Serious adverse reactions have been reported with the concomitant use of SSRIs, SNRIs, tricyclic/tetracyclic antidepressants and MAO inhibitors.
Der bør gå mindst 14 dage fra seponering af rasagilin til iværksættelse af behandling med fluoxetin eller fluvoxamin.
At least 14 days should elapse between discontinuation of rasagiline and initiation of treatment with fluoxetine or fluvoxamine.
Set i lyset af rasagilins MAO-hæmmende virkning anbefales derfor ikke samtidig indgivelse af rasagilin og sympatomimetika, såsom de der findes i nasale og orale ekspektorantia, eller lægemidler mod forkølelser, der indeholder ephedrin eller pseudoephedrin (se pkt.
Therefore, in view of the MAO inhibitory activity of rasagiline, concomitant administration of rasagiline and sympathomimetics such as those present in nasal and oral decongestants or cold medicinal products, containing ephedrine or pseudoephedrine, is not recommended (see section 4.4).
Almindelig: Depression (5,4% vs. 2%), hallucinationer (1,3% vs. 0,7%)
Common: depression (5.4% vs. 2%), hallucinations (1.3% vs. 0.7%) Nervous system disorders
• Smerter i muskler og led
• musculoskeletal pain
In vitro undersøgelser viste, at rasagilin ikke hæmmede cytochrom P450 isoenzymer, CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4 og CYP4A i en koncentration på 1g/ml (svarende til en koncentration, som er 160 gange højere end det gennemsnitlige Cmax  5,98,5 ng/ml hos patienter med Parkinsons sygdom efter indtagelse af 1 mg rasaglin som multipel dosis).
In vitro studies showed that rasagiline at a concentration of 1 μg/ml (equivalent to a level that is 160 times the average Cmax ~ 5.9-8.5 ng/ml in Parkinson's disease patients after 1 mg rasagiline multiple dosing), did not inhibit cytochrome P450 isoenzymes, CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4 and CYP4A.
Navn og adresse på den fremstiller (de fremstillere), der er ansvarlig(e) for batchfrigivelse
A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE Name and address of the manufacturer(s) responsible for batch release
Almindelig: Ortostatisk hypotension (3,9% vs. 0,8%)
Common: orthostatic hypotension (3.9% vs. 0.8%) Gastrointestinal disorders
Der bør udvises forsigtighed ved anvendelse af rasagilin til kvinder, der ammer.
Caution should be exercised when rasagiline is administered to a breast-feeding mother.
Der er rapporteret om symptomer såsom dysfori, hypomani, hypertensive kriser og serotoninsyndrom efter overdosering med rasagilin i doser fra 3 mg til 100 mg.
Symptoms reported following overdose of rasagiline in doses ranging from 3 mg to 100 mg included dysphoria, hypomania, hypertensive crisis and serotonin syndrome.
Lægen vil overveje, hvordan symptomerne kan kontrolleres eller nedsættes.
Tell your doctor if you experience any of these behaviours; they will discuss ways of managing or reducing the symptoms.
Almindelig: Mavesmerter (4,2% vs. 1,3%), forstoppelse (4,2% vs. 2,1%), kvalme og opkastning (8,4%
Common: abdominal pain (4.2% vs. 1.3%), constipation (4.2% vs. 2.1%), nausea and vomiting (8.4% vs. 6.2%), dry mouth (3.4% vs. 1.8%)
Der skal gå mindst 14 dage fra seponering af rasagilin til iværksættelse af behandling med MAO-hæmmere eller pethidin.
At least 14 days must elapse between discontinuation of rasagiline and initiation of treatment with MAO inhibitors or pethidine.
DET SKAL DE VIDE, FØR DE BEGYNDER AT TAGE Rasagilin Mylan
What you need to know before you take Rasagiline Mylan
LÆGEMIDLETS NAVN Rasagilin Mylan 1 mg tabletter
Rasagiline Mylan 1 mg tablets
Det er kendt, at der kan forekomme alvorlige bivirkninger ved samtidig brug af MAO-hæmmere og SSRI'ere, SNRI'ere og tricykliske/tetracykliske antidepressiva.
Serious adverse reactions are known to occur with the concomitant use of SSRIs, SNRIs, tricyclic/tetracyclic antidepressants and MAO inhibitors.
Der har også været rapporteret om tilsvarende tilfælde af impulskontrolforstyrrelser med rasagilin efter markedsføringen.
Similar reports of ICDs have also been received post-marketing with rasagiline.
I en undersøgelse med stigende dosis til patienter i vedvarende levodopabehandling med 10 mg rasagilin dagligt blev der observeret kardiovaskulære bivirkninger (inkl.
In a dose escalation study in patients on chronic levodopa therapy treated with 10 mg/day of rasagiline, there were reports of cardiovascular undesirable reactions (including hypertension and postural hypotension) which resolved following treatment discontinuation.
Almindelig: Muskuloskeletale smerter (6,7% vs. 2,6%), nakkesmerter (2,7% vs. 0%), artritis (1,3% vs.
Musculoskeletal and connective tissue disorders Common: musculoskeletal pain (6.7% vs. 2.6%), neck pain (2.7% vs. 0%), arthritis (1.3% vs.0.7%) Renal and urinary disorders
• Ledsmerter (artralgi)
• joint inflammation (arthritis)
Almindelig: Nedsat appetit (2,4% vs. 0,8%) Psykiske forstyrrelser
Common: decreased appetite (2.4% vs. 0.8%)
Der er ingen erfaring med anvendelse af rasagilin til gravide.
For rasagiline no clinical data on exposed pregnancies is available.
cyster og polypper) Almindelig: Hudkarcinom (1,3% vs. 0,7%) Blod og lymfesystem
Neoplasms benign, malignant and unspecified (including cysts and polyps) Common: skin carcinoma (1.3% vs. 0.7%) Blood and lymphatic system disorders Common: leucopenia (1.3% vs. 0%)
• Meget sjælden (kan forekomme hos færre end 1 ud af 10.000 personer)
• Very rare (may affect up to 1 in 10,000 people)
Rasagilin kan indtages uafhængigt af måltider.
Rasagiline may be taken with or without food.
Aktivt stof: Rasagilin.
What Rasagiline Mylan contains - The active substance is rasagiline.
Nedsat leverfunktion
• decreased weight
Svært nedsat leverfunktion.
Severe hepatic impairment.
Fortæl det også, hvis De ryger eller har til hensigt at holde op med at ryge.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without prescription or if you are smoking or intend to stop smoking.
• Løbenæse (snue)
• runny nose (rhinitis)
• Forstoppelse
• constipation
cyster og polypper) Ikke almindelig: Hudmelanom (0,5% vs. 0,3%) Metabolisme og ernæring
Neoplasms benign, malignant and unspecified (including cysts and polyps) Uncommon: skin melanoma (0.5% vs. 0.3%)
Traumer, forgiftninger og behandlingskomplikationer Almindelig: Faldulykker (4,7% vs. 3,4%)
Common: decreased weight (4.5% vs. 1.5%) Injury, poisoning and procedural complications Common: fall (4.7% vs. 3.4%)
SÅDAN SKAL DE TAGE Rasagilin Mylan
How to take Rasagiline Mylan
Almindelig: Angina pectoris (1,3% vs. 0%) Ikke almindelig: Myokardieinfarkt (0,7% vs. 0%) Luftveje, thorax og mediastinum
Uncommon: myocardial infarction (0.7% vs. 0%) Respiratory, thoracic and mediastinal disorders Common: rhinitis (3.4% vs. 0.7%)
De skal vente mindst 14 dage efter at have stoppet behandling med Rasagilin Mylan, inden De påbegynder behandling med fluoxetin eller fluvoxamin.
You must wait at least 14 days after stopping Rasagiline Mylan treatment and starting treatment with MAO inhibitors or pethidine.
Almindelig: Pludseligt opstået vandladningstrang (1,3% vs. 0,7%) Almene symptomer og reaktioner på administrationsstedet Almindelig: Feber (2,7% vs. 1,3%), utilpashed (2% vs. 0%)
General disorders and administration site conditions Common: fever (2.7% vs. 1.3%), malaise (2% vs. 0%)
Hvis De har taget for meget Rasagilin Mylan
If you stop taking Rasagiline Mylan
Almindelig: Leukopeni (1,3% vs. 0%) Immunsystemet
Common: flatulence (1.3% vs.0%)
Meget almindelig: Hovedpine (14,1% vs. 11,9%)
Very common: headache (14.1% vs. 11.9%) Uncommon: cerebrovascular accident (0.7% vs. 0%)
Almindelig: Rhinitis (3,4% vs. 0,7%)
Common: rash (1.1% vs. 0.3%)